Ninlaro
(Ixazomib Citrate)Phase 3Small molecule
TakedaIxazomib citrate is used to treat multiple myeloma, a type of blood cancer affecting plasma cells in the bone marrow. It works by blocking proteins that help cancer cells survive and grow.[1] Ninlaro is currently being investigated across 6 indications[3], with its most advanced program in Phase 3.[1]
Ninlaro is one of 131 small molecule programs targeting Amyloidosis. It is currently in Phase 3.
6
Indications
30
Total Trials
5
Active Trials
130
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
282 competitors in Multiple Myeloma
#DrugCompanyPhaseTrials
1Fludara
SanofiPhase 3
TALVEY
Johnson & JohnsonPhase 3
Venclexta
AbbViePhase 3
Biaxin
AbbViePhase 3
Xpovio
KKaryopharm Therapeutics Inc
Phase 3
Azatiq
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Ninlaro
TakedaPhase 3
Elranatamab
PfizerPhase 3
Vepesid
AAvyxa
Phase 3
Mozobil
GGenzyme, a Sanofi Company
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Multiple Myeloma18 trials
Show 15 more trials
Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Completed·—·Phase 1/2·NCT02119468·32 enrolled
Plasma Cell Leukemia1 trial
Urothelial Cancer1 trial
8 more indications
Mantle Cell Lymphoma1 trial
Chronic Graft Versus Host Disease1 trial
Waldenstrom macroglobulinemia1 trial
Lymphoma1 trial
Metastatic Kidney Medullary Carcinoma1 trial
Recurrent AL Amyloidosis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ixazomib Citrate. EMBL-EBI & Wellcome Sanger Institute.
- [4]